Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asedebart in Congenital Adrenal Hyperplasia
NCT07859293Phase 2Not yet recruiting
- Sponsor
- Lundbeck
- Start
- Oct 2026
- Primary completion
- Jul 2031
01
Overview
A Phase 2 trial of asedebart in congenital adrenal hyperplasia (CAH), sponsored by Lundbeck. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
asedebart
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on NCT07859293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859293.